

# well

HAN-GINS Indxx Healthcare Megatrend Equal Weight UCITS ETF - Acc

Factsheet | Data as of 31 Jan 2024

## Investment Objective

HAN-GINS Indxx Healthcare Megatrend Equal Weight UCITS ETF (WELL) is designed to capture securities at the cross-roads of medicine and technology which are shaping the future of healthcare. In a single trade, WELL health ETF delivers equal weight exposure to over 100 global companies from the following 10 sub-themes: robotics; nanotechnology; genome sequencing; healthcare trackers; biological engineering; bioinformatics; neuroscience; medical devices; telemedicine and healthcare analytics.

## Why WELL?



### Broad exposure to healthcare innovators

Healthcare innovations are well positioned to deliver strong growth rates as the traditional healthcare sector is undergoing significant change and modernisation in the wake of Covid and thanks to the availability of new technologies. WELL has been updated in 2021 to include innovative themes such as Telemedicine and Healthcare Analytics, which have both proved immensely important in tackling Covid-19.



### Capturing growth more efficiently through equal weighting

WELL health ETF avoids concentration in larger stocks by using an equal weighting methodology. This enables smaller yet innovative companies to better contribute to WELL's performance. The number of companies in each sector will be capped, subject to avoid an overreliance on any-one subtheme.



### ESG screen

WELL only includes companies that comply with the UN Global Compact principles, who are not involved with controversial weapons and who have low fossil fuel exposure.

## Key Risks

1. The value of equities and equity-related securities can be affected by daily stock and currency market movements.
2. Emerging & frontier markets are subject to greater market volatility than developed markets.
3. Investors' capital is fully at risk and investors may not get back the amount originally invested.
4. Exchange rate fluctuations could have a negative or positive effect on returns.

## Trading Information

Exchange	Ticker	RIC	SEDOL	ISIN	CCY
SIX	WELL SW	WELL.S	BMYC3R3	IE00BJQTJ848	CHF
LSE	WELL LN	HAWELL.L	BJVBGL7	IE00BJQTJ848	USD
BMV	WELLIN MF		BMZQGH5	IE00BJQTJ848	USD
LSE	WELP LN	WELP.L	BJVBGM8	IE00BJQTJ848	GBP
Borsa Italiana	WELL IM	WELL.MI	BHRWXD1	IE00BJQTJ848	EUR
Xetra	W311 GY	W311.DE	BJ02354	IE00BJQTJ848	EUR
Euronext Paris	WELL FP	WELP.PA	BPG9MZ4	IE00BJQTJ848	EUR

## Key Facts

Inception Date	04/04/2019
Index	Indxx Global NextGen Healthcare Index NTR
Number of Holdings	100
Base Currency	USD
Index Dividend Yield (Est)	0,31%
Income Treatment	Accumulating
TER	59 bps
Rebalance Frequency	Semi-Annually (June and Dec)
Replication Style	Physical
Registered for Sale	UK, IE, IT, DE, AT, DK, FI, LU, NL, NO, SE, CH
UK Fund Reporting Status	Yes
UCITS Eligible	Yes
ISA Eligible	Yes
SIPP Eligible	Yes
Custodian	J.P. Morgan SE - Dublin Branch
Portfolio Manager	Vident Advisory, LLC
Net Assets of Fund	18.052.804,93 (USD)
Net Assets of Share Class	18.052.804,93 (USD)
Shares Outstanding	2.595.809
SFDR Classification	Article 8

# well

HAN-GINS Indxx Healthcare Megatrend Equal Weight UCITS ETF - Acc

Factsheet | Data as of 31 Jan 2024

## Performance vs Index

Fund	1M	3M	6M	YTD	12M
WELL	10.76%	11.29%	-3.30%	1.66%	1.66%
IHMEQNT	10.85%	11.28%	-3.35%	1.79%	1.79%

Source: Bloomberg, as of 31 Jan 2024. Performance for the fund and the index is shown in USD. Fund performance is shown net of fees with income reinvested where applicable. Please be aware that fees have a detrimental impact on the performance of an ETP. Past performance is not an indicator for future results. \*The fund changed its index on 14th April. The index performance is a composite of the old index prior to this date and the new index after.

### Index Information

The index tracks securities at the cross-roads of medicine and technology which are shaping the future of healthcare. These include over 100 global companies from the following 10 sub-themes: robotics; nanotechnology; genome sequencing; healthcare trackers; biological engineering; bioinformatics; neuroscience; medical devices; telemedicine and healthcare analytics.

### Performance and Volatility Indicators (USD)

Period	Return	Volatility
2024	-5.09%	17.41%
2023	1.66%	19.36%
2022	-29.95%	32.50%
2021	-6.77%	19.00%
2020	27.85%	29.43%


\*Index data up to the 03/04/2019. Fund data from 04/04/2019

Performance before inception is based on back tested data. Back testing is the process of evaluating an investment strategy by applying it to historical data to simulate what the performance of that strategy would have been. Back tested data does not represent actual performance and should not be interpreted as an indication of actual or future performance. Past performance for the index is in USD and shown net of fees. Past performance and back tested index performance is not an indicator for future results and should not be the sole factor of consideration when selecting a product. It is provided for illustrative purposes only. Indices cannot be invested in directly. Investors should read the prospectus of the Issuer ("Prospectus") before investing and should refer to the section of the Prospectus entitled 'Risk Factors' for further details of risks associated with an investment in this product. Source HANetf /Indxx.

### Top 10 Holdings

Company	(%)	Company	(%)
SAREPTA THERAPEUTICS INC	1.36%	TELEX PHARMACEUTICALS LTD	1.19%
SAGE THERAPEUTICS INC	1.24%	BOSTON SCIENTIFIC CORP	1.18%
SHOCKWAVE MEDICAL INC	1.23%	INTUITIVE SURGICAL INC	1.18%
NEUROCRINE BIOSCIENCES INC	1.20%	IRHYTHM TECHNOLOGIES INC	1.16%
PHREESIA INC	1.19%	REGENERON PHARMACEUTICALS	1.16%

### Regional Exposure



- United States 67,08%
- Japan 7,30%
- China 4,29%
- Switzerland 4,24%
- Australia 3,29%
- Sweden 2,99%
- Netherlands 1,97%

### Sub-Theme Breakdown

Sector	Weight (%)
Medical Devices	30.03%
Biological Engineering	27.28%
Genome Sequencing	12.23%
Neuroscience	11.02%
Telemedicine	5.81%
Healthcare Analytics	4.76%
Bioinformatics	4.72%
Robotics	2.91%
Healthcare Trackers	1.16%
Cash	0.07%
Health Technology	0.00%

# well

HAN-GINS Indxx Healthcare Megatrend Equal Weight UCITS ETF - Acc

Factsheet | Data as of 31 Jan 2024

## Partner

HAN-GINS Indxx Healthcare Megatrend Equal Weight UCITS ETF has been developed by HANetf and Gins Global Investment Management, a multi-billion dollar asset management company founded in 2000 with operations in North America, Africa, Middle East and Asia-Pacific. [www.ginsglobal.com](http://www.ginsglobal.com)



## About HANetf

HANetf is an independent provider of UCITS ETFs, working with asset management companies to bring differentiated, modern and innovative exposures to European ETF investors. Via our white-label ETF platform, HANetf provides a complete operational, regulatory, distribution and marketing solution for asset managers to launch and manage UCITS ETFs.

IMPORTANT INFORMATION This factsheet is approved for professional use only.

## Communications issued in the European Economic Area ("EEA").

The content in this document is issued and approved by HANetf EU Limited ("HANetf EU"). HANetf EU is authorised and regulated by the Central Bank of Ireland. HANetf EU is registered in Ireland with registration number 728832.

## Communications issued in the UK

The content in this document is issued and approved by HANetf Limited, an Appointed Representative of Privium Fund Management (UK) Limited ("Privium"), which is authorised and regulated by the Financial Conduct Authority. The registered office of Privium is The Shard, 24th Floor, 32 London Bridge Street, London, SE1 9SG

# well

HAN-GINS Indxx Healthcare Megatrend Equal Weight UCITS ETF - Acc

Factsheet | Data as of 31 Jan 2024

This communication has been prepared for professional investors, but the ETCs and ETFs set out in this communication ("Products") may be available in some jurisdictions to any investors. Please check with your broker or intermediary that the relevant Product is available in your jurisdiction and suitable for your investment profile.

Past performance is not a reliable indicator of future performance. The price of the Products may vary and they do not offer a fixed income.

This document may contain forward looking statements including statements regarding our belief or current expectations with regards to the performance of certain assets classes. Forward looking statements are subject to certain risks, uncertainties and assumptions. There can be no assurance that such statements will be accurate and actual results could differ materially from those anticipated in such statements. Therefore, readers are cautioned not to place undue reliance on these forward-looking statements.

The content of this document is for information purposes and for your internal use only, and does not constitute an investment advice, recommendation, investment research or an offer for sale nor a solicitation of an offer to buy any Product or make any investment.

An investment in an exchange traded product is dependent on the performance of the underlying asset class, less costs, but it is not expected to track that performance exactly. The Products involve numerous risks including among others, general market risks relating to underlying adverse price movements in an Index (for ETFs) or underlying asset class and currency, liquidity, operational, legal and regulatory risks. In addition, in relation to Cryptocurrency ETCs, these are highly volatile digital assets and performance is unpredictable.

The information contained on this document is not, and under no circumstances is to be construed as, an advertisement or any other step in furtherance of a public offering of securities in the United States or any province or territory thereof, where none of the Issuers (as defined below) or their Products are authorised or registered for distribution and where no prospectus of any of the Issuers has been filed with any securities commission or regulatory authority. No document or information on this document should be taken, transmitted or distributed (directly or indirectly) into the United States. None of the Issuers, nor any securities issued by it, have been or will be registered under the United States Securities Act of 1933 or the Investment Company Act of 1940 or qualified under any applicable state securities statutes.

The Issuers:

1. HANetf ICAV, an open-ended Irish collective asset management vehicle issuing under the terms in the Prospectus and relevant Supplement for the ETF approved by the Central Bank of Ireland ("CBI") ("ETF Prospectus") is the issuer of the ETFs. Investors should read the current version of the ETF Prospectus before investing and should refer to the section of the ETF Prospectus entitled 'Risk Factors' for further details of risks associated with an investment in the ETFs. Any decision to invest should be based on the information contained in the ETF Prospectus.
2. HANetf ETC Securities plc, a public limited company incorporated in Ireland, issuing under the terms in the Base Prospectus approved by the Central Bank of Ireland and the final terms of the relevant series ("ETC Securities Documentation") is the issuer of the precious metals ETCs. Investors should read the latest version of the ETC Securities Documentation before investing and should refer to the section of the Base Prospectus entitled 'Risk Factors' for further details of risks associated with an investment in the ETCs. Any decision to invest should be based on the information contained in the ETC Securities Documentation.
3. ETC Issuance GmbH, a limited liability company incorporated under the laws of the Federal Republic of Germany, issuing under the terms in the Prospectus approved by the Bundesanstalt für Finanzdienstleistungsaufsicht ("BaFin") and the final terms ("Cryptocurrency Prospectus") is the issuer of the ETCM ETCs. Investors should read the latest version of the Cryptocurrency Prospectus before investing and should refer to the section of the Cryptocurrency Prospectus entitled 'Risk Factors' for further details of risks associated with an investment in the ETCs contained in the Cryptocurrency Prospectus. Any decision to invest should be based on the information contained in the Cryptocurrency Prospectus.

The ETF Prospectus, ETC Securities Documentation, and Cryptocurrency Prospectus can all be downloaded from [www.hanetf.com](http://www.hanetf.com).

The decision and amount to invest in any Product should take into consideration your specific circumstances after seeking independent investment, tax and legal advice. We do not control and are not responsible for the content of third-party websites.

We believe the information in this document is based on reliable sources, but its accuracy cannot be guaranteed. The views expressed are the views of Hanetf at time of publication and may change. Neither Privium nor Hanetf is liable for any losses relating to the accuracy, completeness or use of information in this communication, including any consequential loss.

FOR SWISS INVESTORS ONLY: The Fund has appointed as Swiss Representative Oligo Swiss Fund Services SA, Av. Villamont 17, 1005 Lausanne, Switzerland, Te l: +41 21 311 17 77, email: [info@oligofunds.ch](mailto:info@oligofunds.ch). The Fund's Swiss paying agent is Helvetische Bank AG. The Prospectus, the Key Investor Information Documents, the Instrument of Incorporation as well as the annual and semi annual reports may be obtained free of charge from the Swiss Representative in Lausanne. In respect of the Shares distributed in or from Switzerland, the place of performance and jurisdiction is at the registered office of the Swiss Representative. The issue and redemption prices are published at each issue and redemption on [www.fundinfo.com](http://www.fundinfo.com) This key investor information is accurate as at 1 May 2020.